Table of Contents
MISSISSAUGA, Ontario – McKesson Canada annoounced this week it has started treating patients with radioligand therapy (RLT) at its newest INVIVA infusion clinic in Toronto, the first time this groundbreaking treatment has been available to patients outside of a hospital setting in Ontario.
"By offering radioligand therapy at INVIVA, we are expanding access to this transformative treatment for patients across the province, while also reinforcing our commitment to advancing patient care," says Dimitris Polygenis, president, Specialty Health, McKesson Canada.
Radioligand therapy represents a breakthrough in nuclear medicine, offering a targeted approach that can significantly improve outcomes for patients with various forms of cancer. By delivering radiation directly to cancer cells, RLT minimizes impact on healthy tissue, resulting in a more precise and effective treatment.
The organization has invested extensively in the infrastructure and certification needed to deliver nuclear medicine safely and effectively. Staff have undertaken comprehensive training, and the clinic has been licensed by the Canadian Nuclear Safety Commission (CNSC), which requires adherence to rigorous quality assurance standards.
“While only a few RLT drugs are currently available in Canada – primarily to treat certain forms of cancer, such as prostate and neuroendocrine tumours – we know this is a rapidly evolving area of medicine,” says Lee Steele, Vice President, INVIVA & Chief Nursing Officer, McKesson Canada. “We felt it was important to invest in building a clinic that was capable of delivering these cutting-edge treatments in order to improve health outcomes for patients in Ontario.”
